<DOC>
	<DOCNO>NCT01682577</DOCNO>
	<brief_summary>The objective study find whether bioavailability PT Dexa Medica 's formulation 4 mg perindopril tert-butylamine tablet equivalent innovator 's product ( Prexum® 4 mg , Servier ) .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations Perindopril 4 mg Tablet Under Fasting Condition</brief_title>
	<detailed_description>The participate subject require overnight fast next morning give orally one tablet test drug ( Perindopril 4 mg tablet PT Dexa Medica ) one tablet reference drug ( Prexum® 4 mg , Servier ) . Blood sample draw immediately take drug ( control ) , 20 , 40 minute , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 , 48 , 96 , 144 , 192 hour drug administration . Three week first drug administration ( washout period ) , procedure repeat use alternate drug . The pharmacokinetic parameter , include AUCt , AUCinf , Cmax , max , t1/2 , determine base concentration perindopril parent compound metabolite perindoprilat , use high-performance liquid chromatography method tandem mass spectrometry detector ( LC-MS/MS ) .</detailed_description>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<criteria>Healthy male female subject Aged 1855 year inclusive A body mass index range 1825 kg/m2 Able participate , communicate well investigator willing give inform consent Nonsmokers Vital sign ( 10 minute rest ) within follow range : systolic blood pressure 100125 mmHg diastolic blood pressure 6080 mmHg pulse rate 6090 bpm Pregnant lactate woman Known hypersensitivity contraindication perindopril Intake prescription drug within 14 day study 's first dose day Intake nonprescription drug , food supplement , herbal medicine within 7 day study 's first dose day History presence liver dysfunction ( ALT , alkaline phosphatase , total bilirubin ≥ 1.5 ULN ) History bleed coagulation disorder Clinically significant ECG abnormality Clinically significant haematology abnormality Renal insufficiency ( plasma creatinine concentration ≥ 1.4 mg/dL ) Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug A donation loss 500 mL ( ) blood within 3 month study 's first dose day A positive hepatitis B surface antigen ( HBsAg ) , antiHCV , antiHIV History drug alcohol abuse within 12 month prior screen study Participation previous study within 3 month study 's first dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Perindopril</keyword>
	<keyword>Perindoprilat</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Angiotensin-converting enzyme inhibitor</keyword>
</DOC>